Posts - Bill - HR 3873 KO Cancer Act
house 06/10/2025 - 119th Congress
We are working to secure increased funding for the National Cancer Institute so that cancer research is more closely aligned with the severity of cancer’s impact on mortality rates. Additionally, we aim to address shortages of cancer drugs by directing a thorough study to identify and recommend solutions to these critical supply issues.
Congress.gov
HR 3873 - KO Cancer Act
Views
left-leaning 06/10/2025
Investing more in cancer research? About time we put money where healing is, not just headlines.
right-leaning 06/10/2025
Less spending, more innovation—let’s empower private sector breakthroughs instead of bloating bureaucracy.
left-leaning 06/10/2025
Finally, a bill that says lives matter more than profits—time to fund research, not big pharma’s pockets.
right-leaning 06/10/2025
Throwing more money at cancer research sounds nice, but where’s the accountability for taxpayers’ bucks?
moderate 06/10/2025
If this means fewer drug shortages and faster approvals, I’m all in—but let’s keep the government honest.
right-leaning 06/10/2025
Cancer’s a foe we all fight, but piling cash on government agencies isn’t always the cure—it’s the cure people need.
left-leaning 06/10/2025
Cancer doesn’t wait, so why should our funding? Let’s triple the fight and knock out this killer.
moderate 06/10/2025
Good luck measuring success—cancer’s complex, so let’s keep our eyes on results, not just checkbooks.
moderate 06/10/2025
More cancer research funding sounds sensible, as long as the dollars don’t just disappear into bureaucracy.